<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">19240722</PMID>
      <DateCompleted>
        <Year>2009</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-1827</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>100</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2009</Year>
              <Month>Mar</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>British journal of cancer</Title>
          <ISOAbbreviation>Br J Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer.</ArticleTitle>
        <Pagination>
          <StartPage>971</StartPage>
          <EndPage>978</EndPage>
          <MedlinePgn>971-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/sj.bjc.6604921</ELocationID>
        <Abstract>
          <AbstractText>Vascular endothelial growth factor (VEGF)-A inhibitors exhibit unseen high responses and toxicity in recurrent epithelial ovarian cancer suggesting an important role for the VEGF/VEGFR pathway. We studied the correlation of VEGF signalling and AKT/mTOR signalling. Using a tissue microarray of clinical samples (N=86), tumour cell immunohistochemical staining of AKT/mTOR downstream targets, pS6 and p4E-BP1, together with tumour cell staining of VEGF-A and pVEGFR2 were semi-quantified. A correlation was found between the marker for VEGFR2 activation (pVEGFR2) and a downstream target of AKT/mTOR signalling (pS6) (R=0.29; P=0.002). Additional gene expression analysis in an independent cDNA microarray dataset (N=24) showed a negative correlation (R=-0.73, P&lt;0.0001) between the RPS6 and the VEGFR2 gene, which is consistent as the gene expression and phosphorylation of S6 is inversely regulated. An activated tumour cell VEGFR2/AKT/mTOR pathway was associated with increased incidence of ascites (chi(2), P=0.002) and reduced overall survival of cisplatin-taxane-based patients with serous histology (N=32, log-rank test, P=0.04). These data propose that VEGF-A signalling acts on tumour cells as a stimulator of the AKT/mTOR pathway. Although VEGF-A inhibitors are classified as anti-angiogenic drugs, these data suggest that the working mechanism has an important additional modality of targeting the tumour cells directly.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Trinh</LastName>
            <ForeName>X B</ForeName>
            <Initials>XB</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Cancer Research Group Antwerp, St Augustinus Hospital, Antwerp, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tjalma</LastName>
            <ForeName>W A A</ForeName>
            <Initials>WA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vermeulen</LastName>
            <ForeName>P B</ForeName>
            <Initials>PB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Van den Eynden</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Van der Auwera</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Van Laere</LastName>
            <ForeName>S J</ForeName>
            <Initials>SJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Helleman</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berns</LastName>
            <ForeName>E M J J</ForeName>
            <Initials>EM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dirix</LastName>
            <ForeName>L Y</ForeName>
            <Initials>LY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Dam</LastName>
            <ForeName>P A</ForeName>
            <Initials>PA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2009</Year>
          <Month>02</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Br J Cancer</MedlineTA>
        <NlmUniqueID>0370635</NlmUniqueID>
        <ISSNLinking>0007-0920</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.-</RegistryNumber>
          <NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D040301">Vascular Endothelial Growth Factor Receptor-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D038762">Ribosomal Protein S6 Kinases, 70-kDa</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009375" MajorTopicYN="N">Neoplasms, Glandular and Epithelial</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D038762" MajorTopicYN="N">Ribosomal Protein S6 Kinases, 70-kDa</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046888" MajorTopicYN="N">Tissue Array Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040301" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-2</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2009</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2009</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2009</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">19240722</ArticleId>
        <ArticleId IdType="pmc">PMC2661789</ArticleId>
        <ArticleId IdType="doi">10.1038/sj.bjc.6604921</ArticleId>
        <ArticleId IdType="pii">6604921</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR (2004) AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene
23(34): 5853–5857</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15208673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JN (2008) Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol
19(3): 577–582</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18024857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger RA (2007) Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol
25(20): 2902–2908</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17617521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol
25(33): 5165–5171</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18024863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol
25(33): 5180–5186</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18024865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Cajal S (2006) Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer
107(8): 1801–1811</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16983702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Ye D, Xie X, Chen B, Lu W (2004) VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol
94(3): 630–635</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15350351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A (2003) A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol
30(5 Suppl 16): 117–124</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14613032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ, Ellis LM (2005) Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene
24(16): 2647–2653</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15735759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev
25(4): 581–611</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15294883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N (2005) VEGF as a therapeutic target in cancer. Oncology
69(Suppl 3): 11–16</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16301831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giantonio BJ, Catalano PJ, Meropol NJ, O′Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson III AB (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol
25(12): 1539–1544</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17442997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, Nooter K, Berns EM (2006) Molecular profiling of platinum resistant ovarian cancer. Int J Cancer
118(8): 1963–1971</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16287073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O′Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med
356(22): 2271–2281</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17538086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huynh H, Teo CC, Soo KC (2007) Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther
6(11): 2959–2966</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18025280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inan S, Vatansever S, Celik-Ozenci C, Sanci M, Dicle N, Demir R (2006) Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta′s in epithelial ovarian tumors. Histol Histopathol
21(10): 1055–1064</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16835828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin
58(2): 71–96</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18287387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelland LR (2005) Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs
10(2): 413–424</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15934876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR (2007a) RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res
13(14): 4261–4270</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17634556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR (2007b) RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res
67(6): 2408–2413</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17363557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin L, Schilder R (2007) Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol
25(20): 2894–2901</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17617520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS (2001) Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood
98(6): 1904–1913</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11535528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol
153(4): 1249–1256</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1853065</ArticleId>
            <ArticleId IdType="pubmed">9777956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagy JA, Herzberg KT, Dvorak JM, Dvorak HF (1993) Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res
53(11): 2631–2643</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8495427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM, Dvorak HF (1995) Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res
55(2): 376–385</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7529135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H (2001) Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ
12(3): 129–135</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11306513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojo F, Najera L, Lirola J, Jimenez J, Guzman M, Sabadell MD, Baselga J, Cajal S (2007) 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res
13(1): 81–89</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17200342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science
219(4587): 983–985</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6823562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sleijfer S, Wiemer E (2008) Dose selection in phase I studies: why we should always go for the top. J Clin Oncol
26(10): 1576–1578</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18332465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stewart M, Turley H, Cook N, Pezzella F, Pillai G, Ogilvie D, Cartlidge S, Paterson D, Copley C, Kendrew J, Barnes C, Harris AL, Gatter KC (2003) The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology
43(1): 33–39</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12823710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabernero J, Rojo F, Burris H, Casado E, Macarulla T, Jones S, Dimitrijevic S, Hazell K, Shand N, Baselga J (2005) A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors. J Clin Oncol
23(16S): 3007</Citation>
        </Reference>
        <Reference>
          <Citation>Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol
26(10): 1603–1610</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18332469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, Turley H, Harris AL, van Dam P, Dirix LY, Vermeulen PB, van Marck EA (2005) Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. Br J Cancer
93(10): 1128–1136</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2361504</ArticleId>
            <ArticleId IdType="pubmed">16251878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van den Eynden GG, Vandenberghe MK, van Dam PJ, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, van Marck EA (2007) Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node. Clin Cancer Res
13(18 Pt 1): 5391–5397</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17875768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE (2007) Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res
13(18 Pt 1): 5341–5347</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17855648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol
24(5): 769–777</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16391297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med
349(5): 427–434</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2275324</ArticleId>
            <ArticleId IdType="pubmed">12890841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeo KT, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF (1993) Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res
53(12): 2912–2918</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8504432</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
